ea0092op-09-01 | Oral Session 9: Thyroid Eye Disease | ETA2023
Douglas Raymond
, Ugradar Shoaib
, Turbin Roger
, Cockerham Kimberly
, Tang Rosa
, Nijhawan Navdeep
, Kossler Andrea
, Boisvert Chantal
, Lee Wendy
, Yen Michael
, Kaufman David
, Yoon Michael
, Bedian Vahe
, Katz Barrett
Objectives: Antagonism of the IGF-1 receptor (IGF-1R) has been shown to reduce TED-related inflammation and proptosis. VRDN-001, a high-affinity antagonist antibody to IGF-1R, has distinct pharmacological properties that may enable differentiated dosing and better efficacy than observed with other antibodies. We assessed VRDN-001 in vitro pharmacology compared with teprotumumab and clinical proof of concept in a phase 1/2 randomized controlled trial (NCT05176639)....